MedTrace Logo

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

NCT06644768 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 137

Last updated 2025-10-09

No results posted yet for this study

Summary

This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations

Conditions

Interventions

DRUG

valemetostat tosylate

Valemetostat will be administered orally once daily until RP2D of valemetostat is determined.

DRUG

pembrolizumab

One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-30
Primary Completion
2028-03-30
Completion
2030-04-30
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Brazil
  • China
  • Japan
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06644768 on ClinicalTrials.gov